Nuvation Bio 2025 Q3 Earnings Revenue Surges 1704.7% Despite Wider Net Loss

Nuvation Bio (NUVB) reported fiscal 2025 Q3 results on Nov 3, 2025, delivering a significant revenue beat while posting a slightly wider-than-expected loss. The company exceeded revenue estimates by $6.26 million and maintained in-line guidance, reflecting strong commercial execution despite ongoing R&D investments.

Revenue

Nuvation Bio’s total revenue surged 1704.7% year-over-year to $13.12 million in Q3 2025, driven by robust performance across its revenue streams. Product revenue from IBTROZI, its lead oncology therapy, contributed $7.72 million, while collaboration and license agreements added $5.40 million, underscoring the drug’s commercial traction and strategic partnerships.

Earnings/Net Income

The company’s net loss widened to $55.79 million ($0.16 per share) in Q3 2025, a 35.4% increase from the prior-year period. Despite the expanded loss, EPS of -$0.16 exceeded the -$0.17 consensus estimate, indicating improved cost management relative to expectations.

Post-Earnings Price Action Review

Nuvation Bio’s stock price experienced mixed short-term performance post-earnings: a 3.18% drop on the latest trading day, a 2.58% weekly gain, and a 39.35% month-to-date surge. The sharp monthly rally suggests strong investor optimism about the company’s long-term growth prospects, particularly around IBTROZI’s market expansion and pipeline advancements. However, the intraday pullback may reflect profit-taking or short-term volatility typical of high-growth biotech stocks.

CEO Commentary

CEO David Hung highlighted Q3 momentum, with 204 new patients starting IBTROZI and a 50-month median duration of response in ROS1-positive NSCLC. He emphasized the drug’s durability as a competitive edge and outlined strategic priorities: advancing the TRUST-IV adjuvant study, securing Japan approval, and optimizing safusidenib’s glioma trial. Hung’s tone remained bullish, framing IBTROZI as a “new standard of care” with long-term patient impact.

Guidance

CFO Philippe Sauvage projected $55 million in annualized IBTROZI revenue if current patient retention holds, with a $25 million Japan milestone payment expected in Q4. Collaboration revenue is anticipated to grow via royalties post-Japan/China reimbursement, though no formal sales guidance was provided. The CFO emphasized confidence in Q3’s performance and long-term durability-driven growth.

Additional News

1. Japan Milestone: Nuvation Bio secured a $25 million milestone payment from Nippon Kayaku ahead of its Q4 Japan approval.

2. China Reimbursement: The company aims for taletrectinib’s inclusion in China’s National Reimbursement Drug List by 2026, expanding access to a key market.

3. Pipeline Updates: Safusidenib’s Phase III glioma trial initiated, while NUV-1511’s DDC platform progress was highlighted as a potential differentiator in oncology innovation.

Nuvation Bio’s shares have surged 96.2% year-to-date, outpacing the S&P 500’s 16.3% gain. Analysts remain overwhelmingly bullish, with a median 12-month price target of $10.00 (48% above its recent close). The Zacks Rank #3 (Hold) reflects mixed earnings estimate revisions, though the company’s strong revenue performance and strategic milestones may drive further optimism.